Inovio Pharmaceuticals (INO) Downgraded by BidaskClub to “Strong Sell”

Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Several other equities analysts have also recently weighed in on INO. Maxim Group set a $12.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 2nd. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 25th. Citigroup initiated coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a “buy” rating and a $10.00 price target for the company. Zacks Investment Research cut Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, ValuEngine cut Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Hold” and an average price target of $19.16.

Shares of Inovio Pharmaceuticals (INO) traded down $0.17 on Friday, reaching $4.25. The company had a trading volume of 1,532,950 shares, compared to its average volume of 1,690,000. The company has a market cap of $369.00, a P/E ratio of -3.60 and a beta of 2.54. Inovio Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The business had revenue of $2.60 million for the quarter, compared to the consensus estimate of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The firm’s revenue for the quarter was down 79.2% compared to the same quarter last year. During the same period last year, the business posted ($0.28) EPS. equities analysts predict that Inovio Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Virginia Retirement Systems ET AL bought a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth approximately $101,000. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $107,000. Neuberger Berman Group LLC bought a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth approximately $115,000. Engineers Gate Manager LP bought a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth approximately $117,000. Finally, Emerald Advisers Inc. PA lifted its stake in shares of Inovio Pharmaceuticals by 84.0% during the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 9,280 shares during the last quarter. Hedge funds and other institutional investors own 32.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/03/inovio-pharmaceuticals-ino-downgraded-by-bidaskclub-to-strong-sell.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply